MannKind Corporation (MNKD) — closed signal from September 27, 2025
Partial Published before the outcome was known, scored automatically when the window closed on December 26, 2025.
Predicted vs. what happened
What happened
Reached 32% of the predicted growth at its peak, without hitting the target.
The thesis — published September 27, 2025
Shares jumped about 29% on much heavier trading than usual after the expanded deal with United Therapeutics, showing strong interest. The short-term trend is rising, while slower trend measures have not fully caught up. A Sept 8 update brought upfront cash and future milestones, easing funding worries. Consider buying on dips near the stated range and add only if momentum clearly improves, as small biotechs can swing widely.
Primary drivers
- Expanded United Therapeutics deal aims to grow products and revenue potential
- Price rose about 29% in a day with far more trading than usual
- Short-term trend looks up, while slower trend gauges have not caught up
- Investor excitement is elevated, but price swings may be larger than normal
How it played out
MNKD: the thesis rose but missed the target
On 2025-09-27, Lyra published a short-term MNKD thesis at $5.53 with expected growth of 40%. The thesis pointed to the expanded United Therapeutics deal, a price rise of about 29% in a day on far heavier trading than usual, an improving short-term trend, and wider price swings around elevated investor interest.
Inside the window from 2025-09-27 to 2025-12-26, MNKD rose to a peak of $6.24 on 2025-11-05, a 12.8% gain. That stayed below the $7.74 target. The target was never reached. The stock ended at $5.79. The thesis partially played out, but it missed its stated goal.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.